Vivos Therapeutics, Inc.
VVOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $15 | $14 | $16 | $17 |
| % Growth | 8.9% | -13.9% | -5.1% | – |
| Cost of Goods Sold | $6 | $6 | $6 | $4 |
| Gross Profit | $9 | $8 | $10 | $13 |
| % Margin | 60% | 59.9% | 62.5% | 74.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $18 | $22 | $29 | $26 |
| SG&A Expenses | $20 | $25 | $34 | $31 |
| Sales & Mktg Exp. | $2 | $2 | $5 | $6 |
| Other Operating Expenses | $1 | $1 | $0 | $1 |
| Operating Expenses | $20 | $26 | $35 | $32 |
| Operating Income | -$11 | -$17 | -$25 | -$19 |
| % Margin | -74.3% | -125.3% | -156.2% | -115.3% |
| Other Income/Exp. Net | $0 | $4 | $1 | $0 |
| Pre-Tax Income | -$11 | -$14 | -$24 | -$20 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$14 | -$24 | -$20 |
| % Margin | -74.1% | -98.4% | -148.8% | -120.2% |
| EPS | -2.22 | -11.14 | -25.9 | -23.89 |
| % Growth | 80.1% | 57% | -8.4% | – |
| EPS Diluted | -2.22 | -11.14 | -25.9 | -23.89 |
| Weighted Avg Shares Out | 5 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 5 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$11 | -$17 | -$24 | -$20 |
| % Margin | -70.2% | -120.8% | -152% | -115.7% |